Anlotinib, a multi-target TKI employed as a last-line treatment for advanced or metastatic NSCLC patients, exerts antiangiogenic and tumor growth-inhibitory effects by targeting the vascular endothelial growth factor receptor (VEGFR), the platelet-derived growth factor receptor (PDGFR), the fibroblast growth factor receptor (FGFR), the stem cell factor receptor (c-Kit), and other kinases[11–12]. The gene discussed is KIT; the disease is neoplasm.